HK1203505A1 - Pyrrole compounds as inhibitors of erk protein kinases and pharmaceutical compositions containing these compounds erk - Google Patents

Pyrrole compounds as inhibitors of erk protein kinases and pharmaceutical compositions containing these compounds erk

Info

Publication number
HK1203505A1
HK1203505A1 HK15104226.1A HK15104226A HK1203505A1 HK 1203505 A1 HK1203505 A1 HK 1203505A1 HK 15104226 A HK15104226 A HK 15104226A HK 1203505 A1 HK1203505 A1 HK 1203505A1
Authority
HK
Hong Kong
Prior art keywords
erk
compounds
inhibitors
pharmaceutical compositions
compositions containing
Prior art date
Application number
HK15104226.1A
Other languages
English (en)
Chinese (zh)
Inventor
Gabriel Martinez-Botella
Michael Hale
Francois Maltais
Qing Tang
Judith Straub
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of HK1203505A1 publication Critical patent/HK1203505A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HK15104226.1A 2004-05-14 2015-05-04 Pyrrole compounds as inhibitors of erk protein kinases and pharmaceutical compositions containing these compounds erk HK1203505A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US57130904P 2004-05-14 2004-05-14

Publications (1)

Publication Number Publication Date
HK1203505A1 true HK1203505A1 (en) 2015-10-30

Family

ID=35106760

Family Applications (2)

Application Number Title Priority Date Filing Date
HK15104226.1A HK1203505A1 (en) 2004-05-14 2015-05-04 Pyrrole compounds as inhibitors of erk protein kinases and pharmaceutical compositions containing these compounds erk
HK18106295.9A HK1247910A1 (zh) 2004-05-14 2018-05-15 吡咯化合物作為erk蛋白激酶的抑制劑以及含有這些化合物的藥物組合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK18106295.9A HK1247910A1 (zh) 2004-05-14 2018-05-15 吡咯化合物作為erk蛋白激酶的抑制劑以及含有這些化合物的藥物組合物

Country Status (26)

Country Link
US (6) US7354939B2 (ja)
EP (5) EP3305776B1 (ja)
JP (1) JP5132305B2 (ja)
CN (1) CN1976919A (ja)
AR (2) AR051735A1 (ja)
AU (1) AU2005245885B2 (ja)
BR (1) BRPI0511111A (ja)
CA (1) CA2566461C (ja)
CY (1) CY1122336T1 (ja)
DK (1) DK3305776T3 (ja)
ES (4) ES2651439T3 (ja)
HK (2) HK1203505A1 (ja)
HU (1) HUE047130T2 (ja)
IL (1) IL179207A0 (ja)
LT (1) LT3305776T (ja)
MX (1) MXPA06013209A (ja)
NO (1) NO20065727L (ja)
NZ (1) NZ551582A (ja)
PL (1) PL3305776T3 (ja)
PT (1) PT3305776T (ja)
RU (1) RU2376299C2 (ja)
SI (1) SI3305776T1 (ja)
TW (1) TW200607803A (ja)
UA (1) UA84930C2 (ja)
WO (1) WO2005113541A1 (ja)
ZA (1) ZA200609975B (ja)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004221881A1 (en) * 2003-03-13 2004-09-30 Vertex Pharmaceuticals Incorporated Compositions useful as protein kinase inhibitors
WO2005100342A1 (en) * 2004-03-26 2005-10-27 Vertex Pharmaceuticals, Incorporated Pyridine inhibitors of erk2 and uses thereof
TW200607803A (en) * 2004-05-14 2006-03-01 Vertex Pharma Pyrrole inhibitors of erk protein kinase, synthesis thereof and intermediates thereto
US8546404B2 (en) 2005-12-13 2013-10-01 Merck Sharp & Dohme Compounds that are ERK inhibitors
ATE485268T1 (de) * 2006-02-16 2010-11-15 Schering Corp Pyrrolidin-derivate als erk-hemmer
CL2008001633A1 (es) * 2007-06-05 2008-12-12 Schering Corp Compuestos derivados de pirrolidin-3-carboxamida; composición farmacéutica; y uso comominhibidores de erk para el tratamiento del cancer.
US8716483B2 (en) 2008-02-21 2014-05-06 Merck Sharp & Dohme Corp. Compounds that are ERK inhibitors
CN102146074B (zh) * 2011-01-26 2013-02-06 江苏先声药物研究有限公司 吡咯衍生物的制备方法及应用
WO2012172093A1 (en) 2011-06-17 2012-12-20 Merz Pharma Gmbh & Co. Kgaa Dihydroindolizine derivate as metabotropic glutamate receptor modulators
RU2696481C2 (ru) 2013-10-14 2019-08-02 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Применение акампросата для модулирования активации erk1/2 в животных моделях fxs и asd и людей с диагностированными fxs и asd
EP3061754A4 (en) 2013-10-23 2017-03-22 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2015095825A1 (en) * 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Cancer treatments using combinations of type 2 mek and erk inhibitors
WO2015095833A1 (en) * 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Treatment of hematologic cancers
WO2015095842A2 (en) * 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Methods and compositions for treating non-erk mapk pathway inhibitor-resistant cancers
JP6727127B2 (ja) * 2013-12-20 2020-07-29 バイオメッド バレー ディスカバリーズ，インコーポレイティド Ｐｉ３ｋ／ａｋｔシグナル経路阻害剤およびｅｒｋ阻害剤の組み合わせを使用するがん処置
CN106211755B (zh) * 2013-12-20 2021-06-22 生物医学谷探索股份有限公司 使用erk和raf抑制剂的组合的癌症治疗
JP6678584B2 (ja) 2013-12-20 2020-04-22 バイオメッド バレー ディスカバリーズ，インコーポレイティド Ｃｄｋ阻害剤およびｅｒｋ阻害剤の組み合わせを使用するがん処置
WO2015095831A1 (en) * 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Cancer treatments using combinations of mtor and erk inhibitors
WO2015095807A1 (en) * 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Cancer treatments using combinations of egfr and erk inhibitors
WO2015095835A1 (en) * 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Methods of modulating radioiodine uptake for the treatment of radioiodine-refractory cancers
JP2017502016A (ja) * 2013-12-20 2017-01-19 バイオメッド バレー ディスカバリーズ，インコーポレイティド １型ｍｅｋ阻害剤およびｅｒｋ阻害剤の組み合わせを使用するがんの処置
US9670177B2 (en) 2015-01-30 2017-06-06 Biomed Valley Discoveries, Inc. Crystalline C21H22Cl2N4O2 malonate
EP3250562A4 (en) * 2015-01-30 2018-07-11 Biomed Valley Discoveries, Inc. Crystalline forms of c21h22ci2n4o2
WO2016187028A1 (en) * 2015-05-15 2016-11-24 Celgene Avilomics Research, Inc. Heteroaryl compounds, synthesis thereof, and intermediates thereto
US10479791B2 (en) * 2015-06-03 2019-11-19 Changzhou Jiekai Pharmatech Co. Ltd Heterocyclic compounds as ERK inhibitors
CA2987963C (en) * 2015-06-03 2023-01-24 Js Innopharm (Shanghai) Ltd. Heterocyclic compounds for treating psoriasis
WO2017068412A1 (en) 2015-10-21 2017-04-27 Otsuka Pharmaceutical Co., Ltd. Benzolactam compounds as protein kinase inhibitors
EP3170822A1 (en) 2015-11-18 2017-05-24 AGV Discovery Azaindole derivatives and their use as erk kinase inhibitors
RU2019107667A (ru) 2016-10-05 2020-11-06 РЕКЬЮРИУМ АйПи ХОЛДИНГС, ЛЛС Спироциклические соединения
GB201706327D0 (en) 2017-04-20 2017-06-07 Otsuka Pharma Co Ltd A pharmaceutical compound
WO2019073435A1 (en) * 2017-10-12 2019-04-18 Novartis Ag COMBINATIONS OF MDM2 INHIBITORS WITH ERK INHIBITORS TO TREAT CANCERS
WO2019180141A1 (en) 2018-03-23 2019-09-26 Bayer Aktiengesellschaft Combinations of rogaratinib
WO2021020841A1 (en) * 2019-07-29 2021-02-04 Standigm Inc. Composition for preventing or treating metabolic liver disease
EP4212531A1 (en) 2022-01-14 2023-07-19 AGV Discovery Azaindole derivatives and their use as erk kinase inhibitors
WO2023169480A1 (zh) * 2022-03-08 2023-09-14 甘李药业股份有限公司 氘代化合物，及其制备方法和应用
WO2023183905A2 (en) * 2022-03-24 2023-09-28 Biomed Valley Discoveries, Inc. Deuterated analogs of pyrrole inhibitors of erk, synthesis thereof and intermediates thereto

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5886026A (en) 1993-07-19 1999-03-23 Angiotech Pharmaceuticals Inc. Anti-angiogenic compositions and methods of use
US5565413A (en) * 1994-12-06 1996-10-15 Zeneca Limited Substituted pyridyl phenyl ketone herbicides
US5472966A (en) * 1995-03-29 1995-12-05 Bristol-Myers Squibb Company Antidepressant heteroarylaminoalkyl derivatives of naphthyl-monazines
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
AU5566300A (en) * 1999-06-22 2001-01-09 Takeda Chemical Industries Ltd. Acylhydrazine derivatives, process for preparing the same and use thereof
MY130778A (en) 2001-02-09 2007-07-31 Vertex Pharma Heterocyclic inhibitiors of erk2 and uses thereof
EP1506189A1 (en) * 2002-04-26 2005-02-16 Vertex Pharmaceuticals Incorporated Pyrrole derivatives as inhibitors of erk2 and uses thereof
EP1554269A1 (en) * 2002-07-09 2005-07-20 Vertex Pharmaceuticals Incorporated Imidazoles, oxazoles and thiazoles with protein kinase inhibiting activities
WO2004009562A1 (en) * 2002-07-18 2004-01-29 Janssen Pharmaceutica, Nv Substituted triazine kinase inhibitors
GB0217780D0 (en) * 2002-07-31 2002-09-11 Glaxo Group Ltd Compounds
PL375447A1 (en) 2002-08-14 2005-11-28 Vertex Pharmaceuticals Incorporated Protein kinase inhibitors and uses thereof
AU2004221881A1 (en) 2003-03-13 2004-09-30 Vertex Pharmaceuticals Incorporated Compositions useful as protein kinase inhibitors
TW200607803A (en) * 2004-05-14 2006-03-01 Vertex Pharma Pyrrole inhibitors of erk protein kinase, synthesis thereof and intermediates thereto

Also Published As

Publication number Publication date
USRE47318E1 (en) 2019-03-26
CN1976919A (zh) 2007-06-06
EP2799434A1 (en) 2014-11-05
NO20065727L (no) 2006-12-12
ZA200609975B (en) 2008-02-27
EP1753738B1 (en) 2014-07-09
ES2513965T3 (es) 2014-10-27
LT3305776T (lt) 2020-01-10
ES2751761T3 (es) 2020-04-01
CA2566461A1 (en) 2005-12-01
EP3943489A1 (en) 2022-01-26
EP3305776B1 (en) 2019-09-25
TW200607803A (en) 2006-03-01
ES2897422T3 (es) 2022-03-01
PT3305776T (pt) 2019-12-17
UA84930C2 (ru) 2008-12-10
JP5132305B2 (ja) 2013-01-30
ES2651439T3 (es) 2018-01-26
AR106755A2 (es) 2018-02-14
USRE46097E1 (en) 2016-08-09
MXPA06013209A (es) 2007-01-16
RU2376299C2 (ru) 2009-12-20
HK1247910A1 (zh) 2018-10-05
AR051735A1 (es) 2007-02-07
AU2005245885B2 (en) 2011-01-20
IL179207A0 (en) 2007-03-08
USRE48266E1 (en) 2020-10-20
US20060106069A1 (en) 2006-05-18
SI3305776T1 (sl) 2020-01-31
BRPI0511111A (pt) 2007-11-27
CY1122336T1 (el) 2021-01-27
AU2005245885A1 (en) 2005-12-01
PL3305776T3 (pl) 2020-03-31
WO2005113541A1 (en) 2005-12-01
JP2007537295A (ja) 2007-12-20
EP2799434B1 (en) 2017-08-02
EP3305776A1 (en) 2018-04-11
USRE49500E1 (en) 2023-04-25
RU2006144445A (ru) 2008-06-20
DK3305776T3 (da) 2019-12-09
EP3608315A1 (en) 2020-02-12
US20230183276A1 (en) 2023-06-15
US7354939B2 (en) 2008-04-08
CA2566461C (en) 2012-07-10
EP1753738A1 (en) 2007-02-21
EP3608315B1 (en) 2021-08-11
HUE047130T2 (hu) 2020-04-28
NZ551582A (en) 2011-01-28

Similar Documents

Publication Publication Date Title
HK1247910A1 (zh) 吡咯化合物作為erk蛋白激酶的抑制劑以及含有這些化合物的藥物組合物
PT1664043E (pt) Composições úteis como inibidores de proteínas quinases
IL179613A0 (en) Compounds and compositions as protein kinase inhibitors
PL1713806T3 (pl) Związki i kompozycje jako inhibitory kinaz białkowych
IL182687A0 (en) Compounds and compositions as protein kinase inhibitors
ZA200704888B (en) Pyrrolopyrazines and pyrazolopyrazines useful as inhibitors of protein kinases
IL192640A0 (en) Inhibitors of tyrosine kinases and pharmaceutical compositions containing the same
TWI372624B (en) Azaindoles useful as inhibitors of jak and other protein kinases
HUS1500049I1 (hu) Protein kináz inhibitor vegyületek és készítmények
EP1673343A4 (en) COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS
EP1670771A4 (en) COMPOUNDS AND COMPOSITIONS INHIBITING PROTEIN-KINASES
HRP20141260T1 (en) Compounds and compositions as protein kinase inhibitors
PL1891066T3 (pl) Związki i kompozycje jako inhibitory kinazy białkowej
EP1841431A4 (en) COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS
EP1613595A4 (en) NOVEL COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF PROTEIN KINASE
IL197724A0 (en) Compounds and compositions as protein kinase inhibitors
EP1765820A4 (en) COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF PROTEIN KINASES
IL198315A0 (en) Compounds and compositions as protein kinase inhibitors
PL1811998T3 (pl) Triazole użyteczne jako inhibitory kinaz białkowych
ZA200508204B (en) Pharmaceutical composition of atorvastatin
SI2332940T1 (sl) Azaindoli, uporabni kot inhibitorji jak in drugih protein-kinaz
EP1658290A4 (en) COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS
EP1877424A4 (en) INHIBITORS OF PROTEIN KINASES AND USES THEREOF
IL179530A0 (en) Novel compounds, pharmaceutical compositions containing same and methods of use for same
ZA200703130B (en) Compounds and compositions as protein kinase inhibitors